Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Feb;29(2):263–270. doi: 10.1128/aac.29.2.263

Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.

J Klastersky, M P Glauser, S C Schimpff, S H Zinner, H Gaya
PMCID: PMC176388  PMID: 3521475

Abstract

The standard regimen used by members of the European Organization for Research on Treatment of Cancer Antimicrobial Therapy Cooperative Group for empiric therapy of febrile neutropenic cancer patients has been treatment with ticarcillin plus amikacin. A three-arm prospective randomized controlled trial was performed to determine whether the extended-spectrum antipseudomonal penicillin azlocillin or the extended-spectrum cephalosporin cefotaxime had more or less efficacy than the beta-lactam in the ticarcillin-plus-amikacin regimen. A total of 742 patients from 22 institutions were evaluated. Single gram-negative rod bacteremias accounted for 83 episodes, and it was among these patients that the prognosis was least satisfactory, leading to a more intensive evaluation of this patient group. In these patients the azlocillin-plus-amikacin regimen resulted in a 66% response rate, compared with a 37% response rate for patients who received cefotaxime plus amikacin (P = 0.080) and a 47% response rate for patients who received ticarcillin plus amikacin (P = 0.207). The patients with gram-negative rod bacteremias and persistently profound granulocytopenia had substantially poorer response rates (37%) than the patients with rising granulocyte counts (73%; P = 0.004). A logistic regression analysis indicated that the following factors also affected infection resolution: beta-lactam utilization in the regimen (azlocillin was better than ticarcillin or cefotaxime), resolution of profound granulocytopenia (less than 100 cells per microliter) during therapy, and susceptibility to the beta-lactam antibiotic.

Full text

PDF
263

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson E. T., Young L. S., Hewitt W. L. Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy. 1978;24(1):45–54. doi: 10.1159/000237759. [DOI] [PubMed] [Google Scholar]
  2. Bergan T. Overview of acylureidopenicillin pharmacokinetics. Scand J Infect Dis Suppl. 1981;29:33–48. [PubMed] [Google Scholar]
  3. Coppens L., Klastersky J. Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin. Antimicrob Agents Chemother. 1979 Mar;15(3):396–399. doi: 10.1128/aac.15.3.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Finley R. S., Fortner C. L., deJongh C. A., Wade J. C., Newman K. A., Caplan E., Britten J., Wiernik P. H., Schimpff S. C. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients. Antimicrob Agents Chemother. 1982 Aug;22(2):193–197. doi: 10.1128/aac.22.2.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Klastersky J., Cappel R., Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother. 1972 Dec;2(6):470–475. doi: 10.1128/aac.2.6.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Klastersky J., Meunier-Carpentier F., Prevost J. M. Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci. 1977 Mar-Apr;273(2):157–167. doi: 10.1097/00000441-197703000-00005. [DOI] [PubMed] [Google Scholar]
  7. Lau W. K., Young L. S., Black R. E., Winston D. J., Linne S. R., Weinstein R. J., Hewitt W. L. Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail. Am J Med. 1977 Jun;62(6):959–966. doi: 10.1016/0002-9343(77)90669-6. [DOI] [PubMed] [Google Scholar]
  8. Sanders C. C., Sanders W. E., Jr, Goering R. V. In vitro antagonism of beta-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother. 1982 Jun;21(6):968–975. doi: 10.1128/aac.21.6.968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Sanders C. C., Sanders W. E., Jr, Goering R. V. In vitro antagonism of beta-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother. 1982 Jun;21(6):968–975. doi: 10.1128/aac.21.6.968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Schimpff S., Satterlee W., Young V. M., Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971 May 13;284(19):1061–1065. doi: 10.1056/NEJM197105132841904. [DOI] [PubMed] [Google Scholar]
  11. Sculier J. P., Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. doi: 10.1016/0002-9343(84)90662-4. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES